Abstract

Chemed Corporation will report second-quarter 2026 results on July 28, 2026 after market close (Post-Mkt), and this preview outlines consensus forecasts for revenue and earnings alongside segment dynamics and stock-price drivers heading into the print.

Market Forecast

Consensus points to a quarter of moderate growth for Chemed Corporation, with revenue estimated at 665.04 million US dollars, up 5.80% year over year, adjusted EPS estimated at 5.60, up 12.45% year over year, and EBIT projected at 96.12 million US dollars, up 2.92% year over year. No explicit gross profit margin or net margin forecast is available, but last quarter’s results provide a baseline with gross profit margin at 32.82% and net profit margin at 10.08%.

VITAS is expected to remain the principal engine of growth in the near term as patient census and care mix trends support revenue, while Roto-Rooter contributes steady top-line performance with ongoing focus on cost discipline and marketing efficiency. Among segments, VITAS appears the most promising near-term growth contributor, having generated 420.02 million US dollars last quarter with supportive operational momentum on utilization and reimbursement; the company-level year-over-year revenue growth last quarter was 1.63%.

Last Quarter Review

Chemed Corporation delivered a stable first quarter with revenue of 657.51 million US dollars (up 1.63% year over year), gross profit margin of 32.82%, GAAP net income to stockholders of 66.30 million US dollars, net profit margin of 10.08%, and adjusted EPS of 5.65 (up 0.36% year over year). The company exceeded consensus expectations modestly, with adjusted EPS surpassing estimates by approximately 6.54% and revenue topping forecasts by about 1.18%.

Segment performance was balanced: VITAS contributed 420.02 million US dollars and Roto-Rooter contributed 237.50 million US dollars; total revenue rose 1.63% year over year, reflecting operational steadiness across the portfolio. Management’s execution on census growth and productivity in VITAS helped offset cost headwinds in Roto-Rooter, where marketing mix dynamics weighed on margins, while consolidated profitability remained resilient.

Current Quarter Outlook

VITAS: Utilization, reimbursement, and operating cadence underpin revenue and earnings resilience

VITAS, Chemed Corporation’s hospice care segment, remains positioned to lead consolidated growth in the current quarter. The forecast for consolidated adjusted EPS at 5.60 (up 12.45% year over year) and EBIT at 96.12 million US dollars (up 2.92% year over year) implies a constructive contribution from VITAS as patient-day volumes and length-of-stay modestly improve and case mix normalizes. In addition, commentary from recent sell-side previews indicates VITAS has built a meaningful Medicare cap cushion in key markets, reducing the risk of cap-related offsets to recognized revenue and allowing better conversion of volume into net revenue.

This quarter’s top-line estimate of 665.04 million US dollars (+5.80% year over year) aligns with continued utilization momentum and consistent referral pipelines. As hospice admissions remain steady, VITAS should benefit from operating leverage in core functions such as care coordination and visit productivity, which can support margin stability even without substantial pricing tailwinds. Management’s prior execution on staffing and visit intensity suggests that care delivery efficiency may help absorb wage inflation and travel costs, sustaining a favorable gross-to-net conversion at the segment level.

A key element to monitor is the balance between inpatient and routine home care, as a shift toward routine care can lower cost intensity and support segment-level gross margin fidelity. With last quarter’s consolidated gross margin at 32.82% and net margin at 10.08% serving as reference points, VITAS’s operating cadence this quarter will be central to achieving the consensus EPS trajectory. Even absent explicit margin guidance, incremental evidence of stable visit intensity, limited cap risk, and reasonable wage containment would corroborate the projected year-over-year uplift in earnings.

Roto-Rooter: Acquired territories, marketing mix, and service intensity set the near-term margin path

Roto-Rooter enters the quarter with incremental territory following the acquisition of formerly independent franchise areas in south Texas in June 2026 for approximately 12.00 million US dollars. While the transaction closed late in the quarter and is unlikely to materially change Q2 revenue, it modestly extends Roto-Rooter’s geographic footprint and should contribute more visibly to run-rate revenue and operating profit over the coming quarters. The acquired areas encompass multiple urban and suburban markets, which can generate a healthy mix of residential and commercial demand, potentially smoothing seasonality.

The segment’s near-term profitability remains tied to marketing mix efficiency and the cost of paid leads, which were cited as headwinds earlier this year. A pivot toward higher-return channels and improvements in conversion rates are the central levers to stabilize margins. Pricing discipline in core plumbing and drain services, combined with service mix optimization and technician productivity initiatives, should help offset increases in labor and materials where possible. The quarter’s consolidated revenue growth expectation of 5.80% year over year implies a supportive demand environment; Roto-Rooter’s ability to translate that demand into margin stability is a key contributor to maintaining the consensus EPS path.

In the context of capital deployment, the June acquisition underscores Chemed Corporation’s measured approach to bolt-on opportunities that can expand service density and route efficiency. While the full margin benefits of integration typically lag the initial close, operational alignment, cross-territory scheduling, and procurement leverage can progressively add basis points to segment-level profitability. The balance of marketing investment, pricing realization, and field productivity will be the decisive factors determining whether Roto-Rooter is accretive to consolidated margin in the second half.

Stock-price drivers this quarter: EPS quality, segment mix, and cash generation

Into the print, the stock’s reaction is likely to be most sensitive to the quality of EPS relative to the 5.60 estimate and the breadth of the revenue beat or miss versus 665.04 million US dollars. A clean top-line beat accompanied by stable gross-to-net conversion and limited one-time items would validate the 12.45% year-over-year EPS growth expectation and could reinforce investor confidence in the back-half trajectory. Conversely, any sign that margin performance depends on unusually low spend or one-off cost reductions, rather than sustainable operating improvements, may temper the reaction even if headline EPS meets consensus.

Segment mix will be a crucial swing factor. A revenue mix skewed toward VITAS, where utilization gains and reimbursement guardrails appear supportive, would likely be perceived as higher quality given the visibility of hospice census and the improving cap cushion. If Roto-Rooter shows steadier marketing efficiency and incremental revenue from newly acquired territories, investors may begin to underwrite incremental second-half operating leverage. However, if paid-lead costs persist at elevated levels or inflationary pressures pinch service margins, the market may discount a portion of the consolidated growth implied by the forecast.

Free cash flow conversion and capital returns also matter this quarter. Chemed Corporation maintained its quarterly cash dividend at 0.60 US dollars per share for the June payout, which underscores balance sheet flexibility. Investors will watch for indications of ongoing capital deployment priorities, particularly the pace of integration and incremental returns from Roto-Rooter’s new territories and any potential investments supporting VITAS’s field operations. Evidence of disciplined spending aligned to organic growth will enhance confidence in sustaining double-digit EPS growth while preserving cash margins.

Beyond the headline metrics, nuanced disclosures could shape the debate on sustainability. In hospice, clarity on admission trends, discharges, and length-of-stay can help investors assess whether the quarter’s revenue uplift is driven by volume, acuity, or mix. In services, detail on marketing ROI, customer conversion rates, and technician productivity will color how the Street extrapolates margin trends. Even absent explicit gross-margin guidance, these operating markers can substantiate the consensus EPS and EBIT contours.

Analyst Opinions

The majority view among the previews we reviewed is constructive and leans positive into the quarter. A notable sell-side institution indicates that VITAS momentum continued after the first-quarter beat and that management enacted a rare post-quarter guidance raise at that time, with improved Medicare cap cushion materially lowering cap risk for the year. The same institution remains cautious on Roto-Rooter given structural headwinds in marketing costs and a mixed macro backdrop for discretionary service spending, yet it raised its price target and maintained a neutral stance, reflecting balanced but supportive fundamentals overall.

Across the limited set of opinions in our collection window, we found no explicitly bearish previews; the preponderance of commentary frames near-term expectations as modestly favorable, with an emphasis on the durability of VITAS execution and the stabilization of Roto-Rooter margins. The constructive skew aligns with consensus forecasts that call for 5.80% year-over-year revenue growth, 12.45% year-over-year adjusted EPS growth, and 2.92% year-over-year EBIT growth. In effect, the prevailing viewpoint is that VITAS can anchor consolidated performance while Roto-Rooter’s late-quarter territory addition and ongoing marketing optimization set the stage for margin steadiness rather than pressure.

This cautiously positive majority view centers on three validations investors seek this quarter. First, confirmation that VITAS’s census and length-of-stay trends remain intact, supporting the revenue estimate of 665.04 million US dollars at the consolidated level with a stable gross-to-net relationship. Second, evidence that Roto-Rooter’s marketing and service mix initiatives can absorb cost pressure while monetizing demand, minimizing the drag from paid-lead intensity. Third, a clean EPS print near or above 5.60, with limited reliance on transient items, would validate the year-over-year rebound implied by the 12.45% growth expectation.

Investors looking to the back half of 2026 will likely weigh how this quarter’s operating narrative translates into forward estimates. Positive confirmation on VITAS utilization and cap cushion can support a thesis of steady revenue progression and margin stability, particularly if wage and travel cost trends remain manageable. For Roto-Rooter, incremental disclosures on the performance of the newly acquired south Texas territories and the cadence of marketing ROI improvement will help the market calibrate the slope of margin recovery. In aggregate, the majority opinion expects Chemed Corporation to deliver a measured step forward in revenue and earnings, with segment-level execution, not macro factors, defining the magnitude of upside or downside versus consensus.